# US 2016/0221940 A1 · Crystalline phase of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) with l-lysine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0221940 A1
- Document ID: US20160221940A1
- Status: Published application
- Kind: A1
- Application number: 15/012,625
- Filed: 2016-02-01
- Published: 2016-08-04
- Earliest claimed: 2012-10-22
- Assignees: Quantum Genomics
- Applicants: Quantum Genomics
- Inventors: Fabrice Balavoine; Jean-Marie Schneider; Gérard Coquerel; Nicolas Couvrat
- Web page: https://patentgrep.com/patent/US20160221940A1

## CPC

- C07C 319/28: Separation; Purification
- A61K 31/145: having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) (isothiourea A61K31/155)
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/06: Antiglaucoma agents or miotics
- C07C 227/42: Crystallisation
- C07C 229/26: having more than one amino group bound to the carbon skeleton, e.g. lysine
- C07C 323/66: containing sulfur atoms of sulfo, esterified sulfo or halosulfonyl groups, bound to the carbon skeleton
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to a new crystalline phase of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and its use, particularly in the pharmaceutical industry, and to processes for preparation thereof. The invention is also directed to pharmaceutical compositions containing at least one crystalline phase of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and to the therapeutic or prophylactic use of such crystalline phase and compositions comprising the same.

## Claims

### Claim 1

A process for the preparation of a crystalline form of ABSD and L-lysine, comprising the steps of:
a. Contacting ABSD, or a salt thereof, or mixtures thereof, with L-lysine,
b. Optionally triggering the formation of a crystalline phase, and/or optionally improving the crystallinity of the crystalline phase,
c. Isolating the crystalline phase obtained in step (b) (or (a)).

### Claim 2 (depends on 1)

The process according to claim 1, wherein the ABSD:L-lysine stoichiometry in step (a) is comprised between about 1:1.5 and 1:2.5.

### Claim 3 (depends on 1)

The process according to claim 1, wherein step (a) is performed in solution.

### Claim 4 (depends on 1)

The process according to claim 1, wherein step (a) is performed in solution and ABSD and L-lysine are suspended in water.

### Claim 5 (depends on 1)

The process according to claim 1, wherein step (a) is performed in solid state, preferably by High Energy Milling.

### Claim 6 (depends on 1)

The process according to claim 1, wherein step (a) is performed in solution and step (b) is performed by addition of an anti-solvent, preferably ethanol.

### Claim 7 (depends on 1)

The process according to claim 1, wherein the improvement of the crystallinity of step (b) is performed by a temperature cycling.

### Claim 8 (depends on 1)

The process according to claim 1, wherein the improvement of the crystallinity of step (b) is performed by a temperature cycling and the temperature cycling is repeated several times.

### Claim 9 (depends on 1)

The process according to claim 1, wherein the improvement of the crystallinity of step (b) is performed by a temperature cycling and the temperature cycling is repeated between 5 and 15 times, preferably 10 times.
